Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

Kyle Blankenship

When Ambys Medicines, a Third Rock Ventures-backed regenerative play, launched in 2018, it came with some serious fanfare for its liver disease-focused approach. Now, after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

Kyle Blankenship

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

After stock slides, Amgen addresses bone density talk on obesity drug

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Third Rock­'s Am­bys clos­es a megaround with the clin­ic still a ways off for its re­gen­er­a­tive cells for liv­er dis­ease

Kyle Blankenship

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Third Rock's Ambys closes a megaround with the clinic still a ways off for its regenerative cells for liver disease

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

After stock slides, Amgen addresses bone density talk on obesity drug

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?